Globus Medical (NYSE:GMED) Updates FY 2026 Earnings Guidance

Key Points

• FY2026 EPS guidance raised to 4.700–4.800 versus the consensus 4.470, while revenue guidance of $3.2 billion is in line with estimates.
• Recent quarter beat expectations, reporting $1.12 EPS (versus $0.92 expected) and $759.85 million in revenue (versus $740.35 million expected), underpinning the outlook.
• Shares fell about $4.17 to $85.05 on heavy volume despite the guidance; analysts maintain a "Moderate Buy" consensus with an average target of $104.36.

Globus Medical (NYSE:GMED - Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.700-4.800 for the period, compared to the consensus estimate of 4.470. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $3.2 billion.

Globus Medical Price Performance

Globus Medical stock traded down $4.17 during midday trading on Thursday, reaching $85.05. The stock had a trading volume of 2,906,424 shares, compared to its average volume of 1,221,776. Globus Medical has a twelve month low of $51.79 and a twelve month high of $101.40. The firm has a market cap of $11.50 billion, a price-to-earnings ratio of 21.59, a PEG ratio of 2.10 and a beta of 1.00. The firm's fifty day simple moving average is $90.00 and its two-hundred day simple moving average is $86.47.

Globus Medical (NYSE:GMED - Get Free Report) last released its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, sell-side analysts predict that Globus Medical will post 4.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on GMED. Truist Financial set a $115.00 price objective on Globus Medical in a research report on Wednesday, February 25th. Citigroup reissued a "market perform" rating on shares of Globus Medical in a research report on Thursday, January 8th. Needham & Company LLC boosted their price objective on shares of Globus Medical from $112.00 to $114.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Zacks Research upgraded shares of Globus Medical from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, March 3rd. Finally, Weiss Ratings reiterated a "hold (c+)" rating on shares of Globus Medical in a research report on Wednesday, April 15th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $104.36.

Insider Buying and Selling at Globus Medical

In other news, EVP Kelly Huller sold 20,000 shares of the business's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 18.38% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Globus Medical

A number of hedge funds have recently modified their holdings of GMED. Invesco Ltd. boosted its stake in shares of Globus Medical by 1,235.2% during the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company's stock worth $339,322,000 after buying an additional 3,595,339 shares during the last quarter. Corient Private Wealth LLC raised its holdings in Globus Medical by 87.4% during the fourth quarter. Corient Private Wealth LLC now owns 89,916 shares of the medical device company's stock worth $7,851,000 after acquiring an additional 41,934 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in Globus Medical during the fourth quarter valued at approximately $499,000. EP Wealth Advisors LLC acquired a new position in Globus Medical during the fourth quarter valued at approximately $607,000. Finally, Fuller & Thaler Asset Management Inc. bought a new position in Globus Medical in the fourth quarter valued at approximately $90,411,000. Institutional investors and hedge funds own 95.16% of the company's stock.

About Globus Medical

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.